Zobrazeno 1 - 10
of 72
pro vyhledávání: '"A. O. Kamphorst"'
Autor:
Peng Li, Haydn Kissick, Rebecca C Obeng, Tahseen H Nasti, Christiane S Eberhardt, Rafi Ahmed, Zhengjia Chen, Warren J Leonard, Suresh S Ramalingam, Andreas Wieland, Annapaola Mariniello, Jeffrey M Switchenko, Kylee Martens, Daniel Y Chang, Donald McGuire, Candace Daugherty, Yuzi Zhang, Rathi Pillai, Alice O Kamphorst
Publikováno v:
BMJ Oncology, Vol 3, Iss 1 (2024)
Objective Immune checkpoint inhibitors (ICI) that block the programmed cell death 1 (PD-1) pathway have shown promise with limited benefit. We and others have shown in small patient cohorts that an early proliferative CD8 T-cell response in the blood
Externí odkaz:
https://doaj.org/article/4cc0e384a52945fa895729f71406f6ed
Autor:
Matthew D. Park, Ivan Reyes-Torres, Jessica LeBerichel, Pauline Hamon, Nelson M. LaMarche, Samarth Hegde, Meriem Belabed, Leanna Troncoso, John A. Grout, Assaf Magen, Etienne Humblin, Achuth Nair, Martina Molgora, Jinchao Hou, Jenna H. Newman, Adam M. Farkas, Andrew M. Leader, Travis Dawson, Darwin D’Souza, Steven Hamel, Alfonso Rodriguez Sanchez-Paulete, Barbara Maier, Nina Bhardwaj, Jerome C. Martin, Alice O. Kamphorst, Ephraim Kenigsberg, Maria Casanova-Acebes, Amir Horowitz, Brian D. Brown, Lucas Ferrari De Andrade, Marco Colonna, Thomas U. Marron, Miriam Merad
Publikováno v:
Nature Immunology. 24:792-801
Autor:
Amaia Lujambio, Miriam Merad, Josep M. Llovet, Augusto Villanueva, Brian D. Brown, Satdarshan P. Monga, Alice O. Kamphorst, Shuang Wang, Lauren Tal Grinspan, Johann von Felden, Akshata Moghe, Aatur D. Singhi, Carlos Villacorta-Martin, Maxime Dhainaut, María Casanova-Acebes, Verónica Miguela, Marc Puigvehi, Daniela Sia, Barbara Maier, Katherine E. Lindblad, Pedro Molina-Sánchez, Erin Bresnahan, Marina Ruiz de Galarreta
Figure S4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a2239f82ab560fbf7e03d16707c4760
https://doi.org/10.1158/2159-8290.22536001
https://doi.org/10.1158/2159-8290.22536001
Autor:
Amaia Lujambio, Miriam Merad, Josep M. Llovet, Augusto Villanueva, Brian D. Brown, Satdarshan P. Monga, Alice O. Kamphorst, Shuang Wang, Lauren Tal Grinspan, Johann von Felden, Akshata Moghe, Aatur D. Singhi, Carlos Villacorta-Martin, Maxime Dhainaut, María Casanova-Acebes, Verónica Miguela, Marc Puigvehi, Daniela Sia, Barbara Maier, Katherine E. Lindblad, Pedro Molina-Sánchez, Erin Bresnahan, Marina Ruiz de Galarreta
Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39a0f77948f1aeb10995dd5c027506a8
https://doi.org/10.1158/2159-8290.22535989
https://doi.org/10.1158/2159-8290.22535989
Autor:
Amaia Lujambio, Miriam Merad, Josep M. Llovet, Augusto Villanueva, Brian D. Brown, Satdarshan P. Monga, Alice O. Kamphorst, Shuang Wang, Lauren Tal Grinspan, Johann von Felden, Akshata Moghe, Aatur D. Singhi, Carlos Villacorta-Martin, Maxime Dhainaut, María Casanova-Acebes, Verónica Miguela, Marc Puigvehi, Daniela Sia, Barbara Maier, Katherine E. Lindblad, Pedro Molina-Sánchez, Erin Bresnahan, Marina Ruiz de Galarreta
PD-1 immune checkpoint inhibitors have produced encouraging results in patients with hepatocellular carcinoma (HCC). However, what determines resistance to anti–PD-1 therapies is unclear. We created a novel genetically engineered mouse model of HCC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09fc6ecb016a0ae658f59e412991d70f
https://doi.org/10.1158/2159-8290.c.6548002.v1
https://doi.org/10.1158/2159-8290.c.6548002.v1
Autor:
Thomas U Marron, Maria Isabel Fiel, Pauline Hamon, Nathalie Fiaschi, Edward Kim, Stephen C Ward, Zhen Zhao, Joel Kim, Paul Kennedy, Ganesh Gunasekaran, Parissa Tabrizian, Deborah Doroshow, Meredith Legg, Ashley Hammad, Assaf Magen, Alice O Kamphorst, Muhammed Shareef, Namita T Gupta, Raquel Deering, Wei Wang, Fang Wang, Pradeep Thanigaimani, Jayakumar Mani, Leanna Troncoso, Alexandra Tabachnikova, Christie Chang, Guray Akturk, Mark Buckup, Steven Hamel, Giorgio Ioannou, Clotilde Hennequin, Hajra Jamal, Haley Brown, Antoinette Bonaccorso, Daniel Labow, Umut Sarpel, Talia Rosenbloom, Max W Sung, Baijun Kou, Siyu Li, Vladimir Jankovic, Nicola James, Sara C Hamon, Hung Kam Cheung, Jennifer S Sims, Elizabeth Miller, Nina Bhardwaj, Gavin Thurston, Israel Lowy, Sacha Gnjatic, Bachir Taouli, Myron E Schwartz, Miriam Merad
Publikováno v:
Lancet Gastroenterol Hepatol
BACKGROUND: Surgical resection of early stage hepatocellular carcinoma is standard clinical practice; however, most tumours recur despite surgery, and no perioperative intervention has shown a survival benefit. Neoadjuvant immunotherapy has induced p
Autor:
Assaf Magen, Pauline Hamon, Nathalie Fiaschi, Leanna Troncoso, Etienne Humblin, Darwin D’souza, Travis Dawson, Matthew D. Park, Joel Kim, Steven Hamel, Mark Buckup, Christie Chang, Alexandra Tabachnikova, Hara Schwartz, Nausicaa Malissen, Yonit Lavin, Alessandra Soares-Schanoski, Bruno Giotti, Samarth Hegde, Raphaël Mattiuz, Clotilde Hennequin, Jessica Le Berichel, Zhen Zhao, Stephen Ward, Isabel Fiel, Colles Price, Nicolas Fernandez, Jiang He, Baijun Kou, Michael Dobosz, Lianjie Li, Christina Adler, Min Ni, Yi Wei, Wei Wang, Namita T. Gupta, Kunal Kundu, Kamil Cygan, Raquel P. Deering, Alex Tsankov, Seunghee Kim-Schulze, Sacha Gnjatic, Ephraim Kenigsberg, Myron Schwartz, Thomas U. Marron, Gavin Thurston, Alice O. Kamphorst, Miriam Merad
Here, we leveraged a large neoadjuvant PD-1 blockade trial in patients with hepatocellular carcinoma (HCC) to search for correlates of response to immune checkpoint blockade (ICB) within T cell-rich tumors. We show that ICB response correlated with t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04351ccef56bbab01aa40ecee8e4b71c
https://doi.org/10.1101/2022.06.22.497216
https://doi.org/10.1101/2022.06.22.497216
Autor:
Thomas U. Marron, Laura Brennan, Pauline Hamon, Maria Isabel Fiel, Stephen C. Ward, Yuan O. Zhu, Edward Kim, Alice O. Kamphorst, Pradeep Thanigaimani, Thomas S. Uldrick, Natalie Lucas, Kathy Wu, Olivia Hapanowicz, Paula King, Siyu Li, Elizabeth Miller, Nina Bhardwaj, Gavin Thurston, Israel Lowy, Sacha Gnjatic, Myron E. Schwartz, Vladimir Jankovic, Miriam Merad
Publikováno v:
Cancer Research. 83:2178-2178
Purpose: We evaluated ctDNA as a pharmacodynamic and predictive biomarker in patients (pts) with resectable HCC treated with cemiplimab (anti-programmed cell death-1). Background: A biomarker-focused study of neoadjuvant cemiplimab in resectable HCC
Autor:
Bérengère Salomé, John P. Sfakianos, Jorge Daza, Andrew Charap, Christian Hammer, Romain Banchereau, Adam M. Farkas, Daniel Geanon, Geoffrey Kelly, Ronaldo M. de Real, Brian Lee, Kristin G. Beaumont, Sanjana Shroff, Yuan Shuo A. Wang, Ying-chih Wang, Tin Htwe Thin, Monica Garcia-Barros, Everardo Hegewisch-Solloa, Emily M. Mace, Li Wang, Timothy O’Donnell, Diego Chowell, Ruben Fernandez-Rodriguez, Mihaela Skobe, Nicole Taylor, Seunghee Kim-Schulze, Robert P. Sebra, Doug Palmer, Eleanor Clancy-Thompson, Scott Hammond, Alice O. Kamphorst, Karl-Johan Malmberg, Emanuela Marcenaro, Pedro Romero, Rachel Brody, Mathias Viard, Yuko Yuki, Maureen Martin, Mary Carrington, Reza Mehrazin, Peter Wiklund, Ira Mellman, Sanjeev Mariathasan, Jun Zhu, Matthew D. Galsky, Nina Bhardwaj, Amir Horowitz
SummaryPD-1/PD-L1-blockade immunotherapies have limited efficacy in the treatment of muscle-invasive bladder cancer (MIBC) and metastatic urothelial carcinoma. Here, we show thatKLRC1(NKG2A) expression associates with improved survival and responsive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1254fb4f5982038f1a365d0992c3c6a3
https://doi.org/10.1101/2022.03.04.482960
https://doi.org/10.1101/2022.03.04.482960
Publikováno v:
Journal of Immunology Research, Vol 2016 (2016)
Externí odkaz:
https://doaj.org/article/6ef8a2984d604ef586f1b16a96864aff